Low intensity ultrasound combination cancer therapies
US-2024226159-A9 · Jul 11, 2024 · US
Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC
Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC · Cooperative Patent Classification (CPC)
Chemical and metallurgical processes, compounds, and materials.
Related technology areas
Mapped technology topics for this CPC code.
| Metric | Value |
|---|---|
| CPC code | C07K14/522 |
| Official title | {Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC} |
| Display label | Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC |
| Total patents | 97 |
Filing trend
Year-over-year patent counts classified under this CPC code.
Filing activity over the last five years is rapidly growing.
| Year | Patents |
|---|---|
| 2015 | 2 |
| 2016 | 5 |
| 2017 | 5 |
| 2018 | 5 |
| 2019 | 10 |
| 2020 | 11 |
| 2021 | 6 |
| 2022 | 12 |
| 2023 | 12 |
| 2024 | 8 |
| 2025 | 15 |
| 2026 | 6 |
Representative patents
Representative publications under this CPC code from precomputed stats, or recent filings when stats are unavailable.
Products and methods for the diagnosis and differentiation of heparin-induced thrombocytopenia from vaccine-induced immune thrombotic thrombocytopenia and non-heparin-induced thrombocytopenia
US-2023406899-A1 · Dec 21, 2023 · US
Lentiviral vectors enabling routing antigens to mhc-ii pathway and inducing cd4+ and cd8+ t-cell responses in a host
US-2023364216-A1 · Nov 16, 2023 · US
Immunocytokines for the treatment of cancer
US-11673931-B2 · Jun 13, 2023 · US
Reducing the risk of major adverse cardiac events
US-2022339253-A1 · Oct 27, 2022 · US
Methods of prognosis and treatment
US-2022326256-A1 · Oct 13, 2022 · US
Inhaled delivery of peptide mimics of cxcl10 for targeted anti-fibrotic therapy
US-2022313777-A1 · Oct 6, 2022 · US
Atomic description of immune complex that causes heparin-induced thrombocytopenia
US-11435362-B2 · Sep 6, 2022 · US
Methods and compositions for treating cancer
US-11419928-B2 · Aug 23, 2022 · US
Using nucleic acids encoding NAP-2 polypeptides to improve cardiac function
US-11413330-B2 · Aug 16, 2022 · US
Methods of prognosis and treatment
US-11385241-B2 · Jul 12, 2022 · US
Fusion proteins comprising a cytokine and scaffold protein
US-2022064245-A1 · Mar 3, 2022 · US
Multi-functional fusion proteins and uses thereof
US-2022056102-A1 · Feb 24, 2022 · US
New immunocytokines for the treatment of cancer
US-2022048966-A1 · Feb 17, 2022 · US
Cxcr3 ligand
US-2022017585-A1 · Jan 20, 2022 · US
Compositions and Methods for use of CXCL12 in Treatment of Bone Disorders
US-2022000980-A1 · Jan 6, 2022 · US
Cleavable activators of cxcr3 and methods of use
US-2021388048-A1 · Dec 16, 2021 · US
Compositions and methods for combating multidrug-resistant bacteria
US-2021300981-A1 · Sep 30, 2021 · US
HETERODIMERIC HUMAN IgG1 POLYPEPTIDES WITH ISOELECTRIC POINT MODIFICATIONS
US-2021284754-A1 · Sep 16, 2021 · US
Fusion protein comprising CCL3 variant and use thereof
US-11046742-B2 · Jun 29, 2021 · US
Frequently asked questions
Answers are generated from the same data shown on this page.
- What is CPC C07K14/522?
- CPC C07K14/522 is the Cooperative Patent Classification code for “Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC.”
- How many patents are filed under CPC C07K14/522 (Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4, KC)?
- Our database includes 97 publications tagged with this CPC code.
- Is patent activity under CPC C07K14/522 growing?
- Publication counts under this code: 8 in 2024 vs 15 in 2025 (latest complete years).